Nexus

About Us
Investment Information
Portfolio Companies
Team
Contact Us
Home



Team The Nexus Team

Nexus is managed by Principals who are supported by Advisors and affiliates in Quincy (MA), San Francisco, London, Munich, Geneva and Tokyo. The Principals and Senior Advisors possess more than 60 years of private equity investment experience between them as well as entrepreneurial and operating success in our target industries. 

The backgrounds of the Principals include technical education and operating experience, successful careers in line management of both established and emerging companies, serving on boards of directors of both public and private companies, and private and public company equity analysis. During their careers, the Nexus team members have managed over $1billion. 

The Principals also have exceptional track records as hands-on investors in adding value to their portfolio companies through strategic guidance, introductions to sources of capital, technology, strategic partners and acquirers, and active participation in assembling the teams and resources necessary for success. 

Jump to:   Principals  |  Senior Advisors  |  Advisors



Principals

Gregory F. Zaic, Principal

Greg has over 27 years of venture capital investment experience, having played a leadership role in the management of a number of venture capital funds. He currently represents Nexus on the Boards of Aethon, Kiyatec and Zipit Wireless. Greg also represented Nexus as a director of Sabal Medical and Cutanea Life Sciences until he negotiated their sale to a European and Asian acquirer respectively. In the past, he has been an active Board member of both public and private corporations, providing assistance and guidance on issues associated with business strategy, corporate expansion, organizational development, and becoming successful publicly traded companies. Selected investments include Biodel (novel insulin formulation, IPO), PerSeptive Biosystems (protein separation systems, acquired by Perkin Elmer) and Infusion Systems (disposable IV pump, acquired by Baxter). 

Prior to joining Nexus, Greg was a general partner of Prince Ventures, a healthcare- focused, venture capital partnership. During the 1980s, Greg was Vice President and Special Limited Partner of the Vista Group where he worked closely with Ed Snape, the leader of Vista's health care practice, and Bob Fleming, Vista's IT partner. From 1972 until 1979, Greg was an executive with Baxter Laboratories. His three member team was responsible for bringing CAPD (Continuous Ambulatory Peritoneal Dialysis) into Baxter, where it became the second-most profitable product line in the company, then accounting for approximately 20% of Baxter's total profits. 

Greg received a BS in aerospace and mechanical engineering from Princeton University; an MS in mechanical engineering the Massachusetts Institute of Technology (MIT); and an MS from MIT's Sloan School of Management.
 

Thomas E. Hancock, Principal

Tom has nearly 20 years of venture capital experience and securities analyst experience. He represents or has represented Nexus on the Boards of Presidio Pharmaceuticals, SpectraAnalysis, EyeGate Pharmaceuticals, MyoScience and Magellan Biosciences. Over the last several years, Tom has led investments in numerous successful private companies, including Panacos Pharmaceuticals and Atricure. 

Prior to joining Nexus, Tom was a Managing Director and Senior Equity Analyst at U. S. Bancorp Piper Jaffray covering publicly traded biopharmaceutical companies and drug discovery supplier companies. While at Piper, he published research notes, reports, industry overviews and technology updates for the benefit of the investment community on Gilead Sciences, Tularik, Human Genome Sciences, Millennium Pharmaceuticals, Applied Biosystems, Charles River Laboratories, Invitrogen and Millipore, among others. Tom also participated in the identification, analysis and recommendation of many companies both pre- and post-IPO. Previously, he was Senior Analyst at Leerink Swann & Company, published equity research on public biopharmaceutical companies including Genentech, Biogen, Amgen and Vertex Pharmaceuticals, among others. Tom was a Senior Research Associate at NationsBanc Montgomery Securities as well as worked in the business development group at Genentech. He was a research scientist at Cor Therapeutics and Genentech. 

Tom holds a B.S. degree in molecular biology and an MBA, both from the University of California, Berkeley.

 

 
Senior Advisors

Edwin Snape, PhD  

Ed has over 35 years of experience in founding, investing in, and guiding the development of many public and private healthcare and specialty materials companies. Ed helped to create Nexus Medical Partners in 2004 and guided its evolution into the present Nexus NMT Capital. Ed continues to work with Nexus as a Senior Advisor. He is currently on the boards of Selah Genomics (molecular diagnostics), Deltex Medical (AIM-listed intra-operative esophageal monitoring) and Spectra Analysis Instruments (FTIR spectroscopy)

Prior to Nexus, Ed was Managing General Partner of The Vista Group, a leading east coast venture capital firm; Chairman of Orien Ventures, a private equity firm with Pacific Rim affiliations; and a Director of the Cygnus Funds, two U.K.-based private equity firms specializing in investments throughout Europe. He was also a founder of an ASEAN Fund based in Indonesia. For these and other funds, Ed served on the Board of Directors and was a guiding force in the development of numerous successful companies. Many of these became highly successful public entities. 

Earlier in his career, he founded and developed the Liposome Company, which became public and was later sold to Elan Corporation for over $700 million. Ed also founded and developed Ergenics, a pioneer in applying metal hydrides for batteries, energy conversion, and transportation. He was also a principal of International Nickel's venture capital arm that made initial stage investments in both Genentech and Biogen. He was also involved in the initial venture capital financing for Emulex Corporation. 

Ed holds several patents in the advanced materials field where he has pioneered various technological innovations and authored numerous technical papers. He has been a recipient of several awards in the material sciences industry, including the AB Campbell Award and the Hunt Silver Medal. 

Ed received BS and PhD degrees in metallurgy from Leeds University, England.
 
 
John F. Rousseau, Jr.  

John has over 30 years of experience in investment management, corporate operations and legal practice. He has been active in guiding a variety of companies, as board member, investor and counsel, in all stages from start-up to being public. He has led investments in a variety of healthcare companies focused in the fields of medical devices, biotechnology, diagnostics, medical instruments and healthcare services. He is co-founder of Nexus Medical Partners, a private equity firm specializing in medical technology and life science investments in the US and Europe, which has evolved into Nexus NMT Capital. Investments with which he has been directly involved and which became public have included Harvard Bioscience (Nasdaq:HBIO), Santarus (Nasdaq:SNTS), ActriCure (Nasdaq:ATRC) and Minrad International (AMEX:BUF). He has served as a Director of several portfolio companies, and currently serves on the boards of Spectra Analysis Instruments; NuvoLase, which has developed and is selling the first FDA-approved laser treatment of onychomycosis; and Seleh Genomics, specializing in molecular diagnostics and next generation sequencing to advance personalized medicine.

Earlier in his career, John held the operating positions of Senior Vice President, Homart Development (a Sears Roebuck subsidiary); Senior Vice President, Spaulding & Slye Company and Chief Executive Officer, Associated Project Control. Prior to beginning his business career, he practiced law for fifteen years, specializing in tax, development and corporate finance transactions with firms in New York, Geneva and Boston, where he was a Senior Partner with the law firm of Hale & Dorr (now Wilmer Hale). John holds a B.A. from Amherst College and a J.D. from Columbia Law School.
 

 
Advisors

Robert C. Fleming  

Bob has been a successful venture capitalist and entrepreneur for over 25 years. In 1995, he founded Prism Venture Partners, a Boston-area venture capital firm. Bob recruited the team, led the development of the strategy, and built the firm to manage $1.25 billion in five funds. He served as Managing Partner until 2006. 

Bob has led investments in a cross-section of industry segments including Communications, Enterprise Software, Internet, and Medical Devices. His investments include industry-leading companies in each area, such as RF Micro Devices (IPO), Eprise (IPO), Telaxis Communications (now Terabeam Wireless) (IPO), Cyberonics (IPO), Intermedia Communications (IPO), Network Equipment Technologies (IPO) Agile Networks (acquired by Lucent), Epicon (acquired by Nortel), and Block Medical (acquired by Hillenbrand). He has played an active role as a director in over thirty companies. 

Prior to founding Prism, Bob was a General Partner with two venture capital firms, Norwest Venture Capital and the Vista Group. While at Vista, he opened and managed the firm's West Coast office from 1988 to 1993, working closely with Ed Snape and Greg Zaic. He returned to New England in 1993 to join Norwest. Earlier in his career, Bob was an early employee of Gartner Group, joining the company in 1983, when it had less than $10 million in revenues. At Gartner, he founded and ran the Local-Area Communications research service. He began his career as a design engineer of data communications equipment at Dataproducts New England, designing early packet switching (X.25) equipment, time-division multiplexers, and network test equipment. 

Bob holds an undergraduate degree in Engineering Sciences from Dartmouth College and an MBA from the Wharton School.


Joseph Harris  

Joe formerly served as Senior Vice President and Director of Corporate Strategy and Development for SmithKline Beecham, currently Glaxo SmithKline, where he analyzed, planned and executed strategic transactions for the company, including acquisitions, divestitures and joint ventures, completing several transactions totaling in excess of $2 billion, including the sale of SB Clinical Laboratories to Quest Diagnostics, Inc. and the sale of Diversified Pharmaceutical Systems to Express Scripts, Inc. Prior to that , he served as Managing Director of Business Development for Eastman Kodak Company, where, he planned and managed 45 strategic transactions, including acquisitions, divestitures, joint ventures and licensing transactions, totaling in excess of $12 billion. 

Joe is a CPA, holds a BS in accounting, an MBA in finance and a law degree from Syracuse University.
 
 
Kester S. Freeman, Jr.  

Kester was most recently Chief Executive Officer of Palmetto Health; the largest integrated healthcare delivery system in South Carolina with net revenues of $1 billion. He is currently a member of the board of directors of the South Carolina Hospital Association, having previously been Chairman, and is the recipient of the Association's 1998 Distinguished Service Award and the Merit Award for Distinguished Service. Kester served as chairman of the PHLIP board, an insurance captive comprised of seven South Carolina hospitals, as the founding chairman of the Carolina HealthChoice Network board of directors, as a member of the American Hospital Association's Organizational Ethics Task Force, and as a COTH representative to the Association of American Medical Colleges Assembly. He served for seven years as a member of the Premier, Inc., board of directors and chaired their audit committee. Kester is Health Sciences South Carolina's first chairman of the board.
 
 
Julian I. Landau  

Julian served as Vice President of Research and Development with Miles Labs (encompassing 250 employees with an annual budget of $30 million), demonstrating his ability to successfully lead major medical device and diagnostic development projects (including diabetes projects) from inception through clinical trials to manufacturing and market introduction.  Earlier, he was a Project Manager with Technicon.  Previous to that, Mr. Landau was a founder of Seratronics, a Cordis Dow medical device spinout.  From 1995 to 2008 Mr. Landau was Managing Director of Access Partners, a seed venture capital fund. During this time Mr. Landau served on the board of directors of Halox Technologies Corporation and Endacea, Inc., and Infratec.  Mr. Landau graduated from Tulane University in Chemical Engineering (1st in class) and the University of California, Berkeley with M.S. in Chemical Engineering. Later he completed an Executive Business Management Program at the Lubin School of Business, Pace University.
 
 
Howard Maibach, M.D.  

Dr. Maibach is a Professor in the Department of Dermatology at the University of California, San Francisco. He is a recognized expert in the field of Dermatology, and specifically, dermatopharmacology and dermatotoxicology. Dr. Maibach has published over 1700 articles on various dermatology-related subjects, and is a frequent lecturer on various subjects related to dermatology. Dr. Maibach has been on the editorial boards of over 30 scientific journals and is a member of 19 professional societies including the American Academy of Dermatology, San Francisco Dermatological Society, and the International Commission on Occupational Health. His bibliography contains 1,950 publications.
 
 
Tadaharu Wakabayashi of Tokyo.  

Tad is past President of SmithKline Beecham Seiyaku and is currently a consultant to Japanese, American and European pharmaceutical companies who desire to develop their business in Japan. He is also an advisor for the Pharmaceutical Division of Nissan Chemical, Co., Ltd. Tad also mediated the establishment of Nisshin Kyorin Seiyaku KK, a joint venture between Nisshin Flour Milling and Kyorin Pharmaceutical in April 1996.